Latest News on TechBio 🍍
⛳ Elix and the Life Intelligence Consortium commercialized an AI drug discovery platform with multiple AI models trained using federated learning
An AI drug discovery platform that incorporates multiple AI models trained using federated learning on data provided by 1️⃣6️⃣ pharmaceutical companies.On July 15, 2025, Elix, Inc (CEO: Shinya Yuki) and the Life Intelligence Consortium (Representative Director: Yasushi Okuno / Headquarters: Osaka) announced that for the first time in the world that they have commercialized an AI drug discovery platform that incorporates multiple AI models trained using federated learning on data provided by 1️⃣6️⃣ pharmaceutical companies (Elix and LINC Become the First in the World to Commercialize an AI Drug Discovery Platform Incorporating Federated Learning-Based AI Models).
Elix, in partnership with the Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University, developed the federated learning library kMoL enabling multiple companies to collaboratively develop a suite of AI models without disclosing their confidential data externally. In particular, 1️⃣6️⃣ pharmaceutical companies participated in building these federated learning-based models, which are now implemented on Elix Discovery™, Elix’s proprietary AI drug discovery platform.